ClinicalTrials.gg
RecruitingNCT06048614Updated May 23, 2025

Saline Enema Administration in Meconium Obstruction of Prematurity and Impact on the Resolution, Feeds, Microbiome, and Gut-brain Axis.

An interventional study of Saline Enema (SE) and Glycerin Suppository in Meconium Obstruction of Prematurity, sponsored by KK Women's and Children's Hospital. Recruiting at 2 sites in Singapore. Open to participants aged 1 Day to 36 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-23.

Sponsored by KK Women's and Children's Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
1 Day to 36 Weeks
Sex
All
01

Study summary

The goal of this clinical trial is to study the effect of twice-daily saline enema (SE) in the treatment obstruction of prematurity (MOP) in infants with the birth weight ≤1.25kg. The main questions, the trial aims to answer are

  1. To validate the finding of our pilot study which had shown that twice-daily SE reduces the time to reach full enteral feeds in premature infant as compared to premature infant treated with Glycerine Suppository (GS), in a larger cohort. Infant with MOP fails to pass meconium in the first 48 hours of life and develop symptoms and signs like abdominal distension and feed intolerance.
  2. The other aims of this study are to test whether the intervention is

    1. Effective treatment for MOP
    2. Reduce the duration of ICU stay
    3. Reduce the rate of necrotizing enterocolitis, sepsis, Total Parenteral Nutrition (TPN) days and number of intravenous catheter days
  3. The study also wants to explore the impact of this intervention on the gut microbiome, gut-brain interaction and immune response of the new-born.
Read the detailed description

Very low birth weight infants (VLBW ≤ 1.5 kg) constitute more than 60% of bed occupancy in level III neonatal units. They face the risk of 10-50% long-term disability, and their initial healthcare cost ranges from S$50,000 to 1 million, an important healthcare issue.

The incidence of meconium obstruction of prematurity (MOP) is 20-30% in extremely low birth weight (ELBW ≤ 1 kg) infants. The intervention based on the current standard of care increase the risk of laparotomy necrotizing enterocolitis, intestinal perforation, and neurodevelopmental risks posed by general anaesthesia. Our published pilot RCT demonstrated that saline enema (SE) is an effective, feasible, and safe intervention to reduce the time to reach full enteral feeds and is a potentially effective treatment for MOP in ELBW (\< 1 kg) infants.

Our primary hypothesis is that Infants with Twice-daily high-volume SE (20-40 ml/kg/day) intervention will result in reduced time to reach full enteral feeds compared to infants treated with conventional management with Glycerin suppository (GS) in (≤1.25kg) infants with MOP. Our exploratory hypothesis is that SE will have a protective effect on the gut microbiome, inflammatory and immune response in preterm infants.

Ninety-five infants born over three years in KK Hospital (KKH) and Singapore General Hospital (SGH) will be enrolled and randomized at 48 hours or later to receive SE or GS. The standardized protocol will be used for the accreditation and administration of SE. Primary, secondary, and exploratory outcomes data, including treatment failure data, will be recorded. Infants will be followed up to 36 weeks of gestation or discharge, whichever is earlier. Maternal and infant characteristics, inflammatory and immune response, and safety outcome data will be collected.

If the findings of our pilot trial are confirmed, the protocol can become the standard of care in preterm infants with MOP. Additionally, significant healthcare cost savings will be realized alongside an improved understanding of the Microbiome, immune and inflammatory response pertaining to the gut.

02

Conditions studied

  • Meconium Obstruction of Prematurity
03

In context

Lead sponsor

KK Women's and Children's Hospital is the lead sponsor of 137 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day to 36 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Criteria A: For infant presenting with early onset of MOP

    1. Birth weight 500 - 1250 gram
    2. ≥ 23 weeks gestation
    3. No BO for 48 hours
    4. BO present but with a small amount or stain of meconium
    5. Feeds intolerance or abdominal X-ray showing dilated loops of bowel
  • Criteria B: For infant presenting with Late onset of MOP

    1. Birth weight 500 - 1250 gram
    2. ≥ 23 weeks gestation
    3. Infants who passed meconium initially and develop evidence of meconium obstruction at a later age (feed intolerance or vomiting and abnormal abdominal X-ray with or without abdominal distension)

Exclusion criteria

Exclusion Criteria:

Infants that:

  1. Neuromuscular disorder
  2. Moderate or severe asphyxia
  3. Inability to start enteral feeding, which continued for 3 consecutive days before 2 weeks of post-natal age for reasons unrelated to meconium inspissation or its complication
  4. Without parental consent
  5. Aggravated medical instability
  6. Single mothers \< 21 years
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
95 participants (estimated)

Study arms

  • Experimental
    Intervention Arm (Saline Enema Arm)

    After randomisation, infant who allocated with intervention group will proceed with SE with normal saline (20-40ml/kg twice daily) earliest at 48 to 72 hours of age. Then continue until 2 days of yellow stools/ 110ml/kg/day of oral feeds; whichever is earlier. SE are recommended if baby do not do bowel opening (BO) for 2 days before reaching full feeds

    Procedure: Saline Enema (SE)

  • Active comparator
    Control Arm (Glycerin Suppository Arm)

    Infants randomized to GS received the standard management protocol for meconium retention in the unit. GS (2,000 mg, a quarter unit, four doses 12 h apart) were administered to infants earliest at 48 hour to 72 hours of birth, with subsequent once-daily GS being administered at the discretion of the managing team. Infants who were diagnosed with meconium obstruction later in the first 2 weeks of life were also treated with glycerin suppositories for 48 hrs, with subsequent once-daily GS being administered at the discretion of the managing team. Infants who failed to respond to glycerin suppositories were referred to the surgical team by the managing team The subsequent management of meconium retention was at the surgeon's discretion and included continued GS by the surgical team, contrast enema or surgical interventions performed in escalating order as mentioned.

    Drug: Glycerin Suppository

Interventions

  • ProcedureSaline Enema (SE)

    infant who allocated with intervention group will proceed with SE with normal saline (20-40ml/kg twice daily) at 48 hours of age. Then continue until 2 days of yellow stools/ 110ml/kg/day of oral feeds; whichever is earlier. SE are recommended if baby do not do bowel opening (BO) for 2 days before reaching full feeds Failure to resolve the MOP with SE will be designated as treatment failure and managed with contrast enema or Laparotomy by paediatric surgeons, following a formal referral.GS is not allowed in intervention arm

  • DrugGlycerolStudies of GlycerolGlycerol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Infants randomized to GS received the standard management protocol for meconium retention in the unit. GS (2,000 mg, a quarter unit, four doses 12 h apart) were administered to infants earliest at 48 hour to 72 hours of birth, with subsequent once-daily GS being administered at the discretion of the managing team. Infants who were diagnosed with meconium obstruction later in the first 2 weeks of life were also treated with glycerin suppositories for 48 hrs, with subsequent once-daily GS being administered at the discretion of the managing team. Infants who failed to respond to glycerin suppositories were referred to the surgical team by the managing team The subsequent management of meconium retention was at the surgeon's discretion and included continued GS by the surgical team, contrast enema or surgical interventions performed in escalating order as mentioned.

06

What researchers measure

Primary outcomes

  1. Time to reach full enteral feeds in days

    Time to reach full enteral feeds is measured from birth to the time infant reaches full oral milk feeds. Full oral milk feed is defined as milk volume of 110ml/kg/day. The total parenteral nutrition is discontinued when infant reaches milk feed volume of 110ml/kg/day. Rationale: SE loosens the thick and sticky meconium by saline absorption and triggers effective and strong peristaltic contractions, thereby leading to the evacuation of meconium from the gut. The evacuation of meconium leads to the resolution of the gut obstruction, thereby enhancing feed tolerance in premature infants with meconium obstruction of prematurity.

    Time frame: Before 36 weeks of corrected age of discharge of the infant

Secondary outcomes

  1. Rate of treatment failure

    Treatment failure is defined as the need to use additional treatment measures, apart from the study intervention to resolve MOP in the study cohort.

    Time frame: Before 36 weeks of corrected age of discharge of the infant

  2. Rate of (a) Culture positive sepsis (b) Necrotising enterocolitis.

    Rationale: If twice daily SE leads to the shortening of time to reach full enteral feeds, resolution of MOP, and promote friendly bacteria microbiome, then it has the potential to reduce NICU stay, risk of necrotising enterocolitis, risk of sepsis, duration of total parenteral nutrition, duration of PICC and overall cost of care.

    Time frame: Before 36 weeks of corrected age of discharge of the infant

  3. Duration in days of (a) ICU stay (b) Total parenteral nutrition (c) PICC days.

    Rationale: If twice daily SE leads to the shortening of time to reach full enteral feeds, resolution of MOP, and promote friendly bacteria microbiome, then it has the potential to reduce NICU stay, risk of necrotising enterocolitis, risk of sepsis, duration of total parenteral nutrition, duration of PICC and overall cost of care.

    Time frame: Before 36 weeks of corrected age of discharge of the infant

  4. Overall cost of care calculated in SGD at the time of discharge

    Rationale: If twice daily SE leads to the shortening of time to reach full enteral feeds, resolution of MOP, and promote friendly bacteria microbiome, then it has the potential to reduce NICU stay, risk of necrotising enterocolitis, risk of sepsis, duration of total parenteral nutrition, duration of PICC and overall cost of care.

    Time frame: Before 36 weeks of corrected age of discharge of the infant

Other outcomes

  1. Identification and quantification of bacteria from meconium/stool samples by DNA sequencing and analysis of top 50 bacteria Genus

    Bacteria are identified from meconium/stools samples, collected at birth and weekly interval till discharge or 36 weeks of gestation

    Time frame: Before 36 weeks of corrected age of discharge of the infant

  2. To measure the serum level of IL 6 in pg/ml

    Use Olink Target 48 platform to measure Rationale: To explore the relationship between gut microbiome and gut-brain axis

    Time frame: Before 36 weeks of corrected age of discharge of the infant

  3. To measure the serum level of neurotransmitters noradrenaline in pg/L

    Use Norepinephrine ELISA Kit from abcam to measure

    Time frame: Before 36 weeks of corrected age of discharge of the infant

  4. Measure serum levels of dopamine in arbitrary units (peak area of analyte divided by peak area of an internal standard)

    Use Norepinephrine ELISA Kit from abcam to measure

    Time frame: Before 36 weeks of corrected age of discharge of the infant

  5. Measure serum levels of serotonin in arbitrary units (peak area of analyte divided by peak area of an internal standard)

    Use Norepinephrine ELISA Kit from abcam to measure

    Time frame: Before 36 weeks of corrected age of discharge of the infant

  6. Measure serum levels of GABA in arbitrary units (peak area of analyte divided by peak area of an internal standard)

    Use Norepinephrine ELISA Kit from abcam to measure

    Time frame: Before 36 weeks of corrected age of discharge of the infant

  7. Measure level of Propionate in µM

    Use Short Chain Fatty Acid Panel to measure

    Time frame: Before 36 weeks of corrected age of discharge of the infant

  8. Measure level of Butyrate in µM

    Use Short Chain Fatty Acid Panel to measure

    Time frame: Before 36 weeks of corrected age of discharge of the infant

  9. Measure level of Acetate in µM

    Use Short Chain Fatty Acid Panel to measure

    Time frame: Before 36 weeks of corrected age of discharge of the infant

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Unger A, Goetzman BW, Chan C, Lyons AB 3rd, Miller MF. Nutritional practices and outcome of extremely premature infants. Am J Dis Child. 1986 Oct;140(10):1027-33. doi: 10.1001/archpedi.1986.02140240073029. PubMed 3092638 ↗
  • Chathas MK, Paton JB, Fisher DE. Percutaneous central venous catheterization. Three years' experience in a neonatal intensive care unit. Am J Dis Child. 1990 Nov;144(11):1246-50. doi: 10.1001/archpedi.1990.02150350078030. PubMed 2239866 ↗
  • Stoll BJ, Gordon T, Korones SB, Shankaran S, Tyson JE, Bauer CR, Fanaroff AA, Lemons JA, Donovan EF, Oh W, Stevenson DK, Ehrenkranz RA, Papile LA, Verter J, Wright LL. Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr. 1996 Jul;129(1):63-71. doi: 10.1016/s0022-3476(96)70191-9. PubMed 8757564 ↗
  • Shim SY, Kim HS, Kim DH, Kim EK, Son DW, Kim BI, Choi JH. Induction of early meconium evacuation promotes feeding tolerance in very low birth weight infants. Neonatology. 2007;92(1):67-72. doi: 10.1159/000100804. Epub 2007 Mar 14. PubMed 17356305 ↗
  • Krasna IH, Rosenfeld D, Salerno P. Is it necrotizing enterocolitis, microcolon of prematurity, or delayed meconium plug? A dilemma in the tiny premature infant. J Pediatr Surg. 1996 Jun;31(6):855-8. doi: 10.1016/s0022-3468(96)90153-0. PubMed 8783123 ↗
  • Emil S, Nguyen T, Sills J, Padilla G. Meconium obstruction in extremely low-birth-weight neonates: guidelines for diagnosis and management. J Pediatr Surg. 2004 May;39(5):731-7. doi: 10.1016/j.jpedsurg.2004.01.027. PubMed 15137008 ↗
  • Haiden N, Norooz F, Klebermass-Schrehof K, Horak AS, Jilma B, Berger A, Repa A. The effect of an osmotic contrast agent on complete meconium evacuation in preterm infants. Pediatrics. 2012 Dec;130(6):e1600-6. doi: 10.1542/peds.2011-3634. Epub 2012 Nov 26. PubMed 23184118 ↗
  • Broussard DL. Gastrointestinal motility in the neonate. Clin Perinatol. 1995 Mar;22(1):37-59. PubMed 7781255 ↗
  • Dumont RC, Rudolph CD. Development of gastrointestinal motility in the infant and child. Gastroenterol Clin North Am. 1994 Dec;23(4):655-71. PubMed 7698826 ↗
  • Campbell BG, Couceyro P, Keana JF, Weber E. N-methyl-D-aspartate receptor-mediated contractions of the guinea pig ileum longitudinal muscle/myenteric plexus preparation: modulation by phencyclidine and glycine receptors. J Pharmacol Exp Ther. 1991 May;257(2):754-66. PubMed 1674535 ↗
  • Siddiqui MM, Drewett M, Burge DM. Meconium obstruction of prematurity. Arch Dis Child Fetal Neonatal Ed. 2012 Mar;97(2):F147-50. doi: 10.1136/adc.2010.190157. Epub 2010 Nov 29. PubMed 21115553 ↗
  • Juang D, Snyder CL. Neonatal bowel obstruction. Surg Clin North Am. 2012 Jun;92(3):685-711, ix-x. doi: 10.1016/j.suc.2012.03.008. Epub 2012 Apr 17. PubMed 22595716 ↗
  • Kim YJ, Kim EK, Kim ES, Kim HS, Choi JH, Cheon JE, Kim WS, Kim IO, Park KW. Recognition, diagnosis and treatment of meconium obstruction in extremely low birth weight infants. Neonatology. 2012;101(3):172-8. doi: 10.1159/000330850. Epub 2011 Oct 22. PubMed 22024741 ↗
  • Garza-Cox S, Keeney SE, Angel CA, Thompson LL, Swischuk LE. Meconium obstruction in the very low birth weight premature infant. Pediatrics. 2004 Jul;114(1):285-90. doi: 10.1542/peds.114.1.285. PubMed 15231948 ↗
  • Cho HH, Cheon JE, Choi YH, Lee SM, Kim WS, Kim IO, Shin SM, Kim EK, Kim HS, Choi JH, You SK. Ultrasound-guided contrast enema for meconium obstruction in very low birth weight infants: Factors that affect treatment success. Eur J Radiol. 2015 Oct;84(10):2024-31. doi: 10.1016/j.ejrad.2015.06.006. Epub 2015 Jun 7. PubMed 26159485 ↗
  • Ibrahim T, Li Wei C, Bautista D, Sriram B, Xiangzhen Fay L, Rajadurai VS. Saline Enemas versus Glycerin Suppositories to Promote Enteral Feeding in Premature Infants: A Pilot Randomized Controlled Trial. Neonatology. 2017;112(4):347-353. doi: 10.1159/000477999. Epub 2017 Aug 3. PubMed 28768263 ↗
  • Paradiso VF, Briganti V, Oriolo L, Coletta R, Calisti A. Meconium obstruction in absence of cystic fibrosis in low birth weight infants: an emerging challenge from increasing survival. Ital J Pediatr. 2011 Nov 14;37:55. doi: 10.1186/1824-7288-37-55. PubMed 22082231 ↗
  • Livingston MH, Shawyer AC, Rosenbaum PL, Williams C, Jones SA, Walton JM. Glycerin enemas and suppositories in premature infants: a meta-analysis. Pediatrics. 2015 Jun;135(6):1093-106. doi: 10.1542/peds.2015-0143. Epub 2015 May 18. PubMed 25986027 ↗
  • Vinson AE, Houck CS. Neurotoxicity of Anesthesia in Children: Prevention and Treatment. Curr Treat Options Neurol. 2018 Oct 13;20(12):51. doi: 10.1007/s11940-018-0536-z. PubMed 30315440 ↗
  • Saenz de Pipaon Marcos M, Teresa Montes Bueno M, Sanjose B, Gil M, Parada I, Amo P. Randomized controlled trial of prophylactic rectal stimulation and enemas on stooling patterns in extremely low birth weight infants. J Perinatol. 2013 Nov;33(11):858-60. doi: 10.1038/jp.2013.86. Epub 2013 Aug 1. PubMed 23907087 ↗
  • Nakaoka T, Nishimoto S, Tsukazaki Y, Santo K, Higashio A, Kamiyama M, Uehara S, Yoneda A, Tanaka Y, Ichiba H. Ultrasound-guided hydrostatic enema for meconium obstruction in extremely low birth weight infants: a preliminary report. Pediatr Surg Int. 2017 Sep;33(9):1019-1022. doi: 10.1007/s00383-017-4129-9. Epub 2017 Jul 25. PubMed 28744798 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Aug 2027, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2023
First posted
Sep 21, 2023
StartActual
Jan 2, 2024
Primary completionEst.
Aug 31, 2027
CompletionEst.
Dec 31, 2027
Last update
May 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06048614
Collaborators
Singapore General Hospital, Genome Institute of Singapore, Translational Immunology Institute, Duke-NUS Graduate Medical School
Responsible party
Thowfique Kadavukarayil Ibrahim (Senior Consultant(Assistant Professor), KK Women's and Children's Hospital) — Principal investigator
First posted
Sep 21, 2023
Start date
Jan 2, 2024
Primary completion
Aug 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 23, 2025

Study contacts

Seow Ching Li, Biomedical
Contact
li.seow.ching@kkh.com.sg
63948005 ext. 8005
Kathy Liaw, Biomedical
Contact
kathy.liaw.c.s@singhealth.com.sg
63948939 ext. 8939
Thowfique Ibrahim, FRCPCH, FAMS
principal investigator · Singhealth Duke-NUS Medical School, NUS and LKC Medical School

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion